January 24, 2018 / 1:47 PM / 3 months ago

BRIEF-Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/Mabthera

Jan 24 (Reuters) - Pfizer Inc:

* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN®/MABTHERA®

* PFIZER INC - PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN(®)/MABTHERA(®)

* PFIZER INC - RESULTS FROM COMPARATIVE REFLECTIONS B3281006 STUDY DEMONSTRATE EQUIVALENCE IN PATIENTS WITH INDOLENT FOLLICULAR LYMPHOMA

* PFIZER INC - REFLECTIONS B3281006, A COMPARATIVE SAFETY AND EFFICACY STUDY OF PF-05280586 VERSUS MABTHERA(®) (RITUXIMAB-EU), MET ITS PRIMARY ENDPOINT

* PFIZER - TRIAL DEMONSTRATED EQUIVALENCE IN OVERALL RESPONSE RATE FOR FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below